

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

14 December 2023

Cleansing Notice

Zoono Group Limited (**Company**) advises that it has issued 10,432,887 fully paid ordinary shares (**Shares**) at 2.7c per Share to raise \$281,687 together with 1,700,000 Shares at a deemed issue price of 5c per Share to employees as a short-term incentive. Employees agreed to take Shares in the Company rather than cash to protect the Company's cash position. Employees included the following to key management personnel:

Name of KMP	Name of registered Holder	Number of Shares
Paul Ravlich	Ravlich Trustee Limited	1,000,000
Lewis Mackinnon	Lewis Andrew Craig Mackinnon	500,000

Zoono gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

The Corporations Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A. By giving this Notice the shares noted above will fall within the exemption in section 708A(5) of the Corporations Act.

For the purposes of section 708A(6) of the Corporations Act, Zoono gives notice that:

1. The Company issued shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. This Notice is being given under 708A(5)(e) of the Corporations Act;
3. As at the date of this notice, the Company has complied with:
 - a. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
4. As at the date of this Notice, there is no information that is 'excluded information' within the meanings of sections 7087A(7) and 708A(8) of the Corporations Act.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:**Zoono Group Limited**

Paul Hyslop
Group MD
M: +64 21 659 977
E: paul.hyslop@zoono.com

Paul Ravlich
Group CFO
M: +64 21 075 9176
E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'ZOONO molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the Company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com